Overview
CJC-1295 (No DAC), also referenced in scientific literature as Modified GRF(1-29) or Mod GRF 1-29, is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of 29 amino acids. This laboratory-synthesized peptide represents a truncated and modified version of the endogenous GHRH(1-44) sequence, engineered with specific amino acid substitutions to enhance metabolic stability and resist enzymatic degradation under experimental conditions.
In experimental biology, CJC-1295 (No DAC) is utilized to investigate growth hormone (GH) secretion dynamics, pulsatile release patterns, and downstream IGF-1 signaling cascades. Unlike CJC-1295 with DAC (Drug Affinity Complex), this variant lacks the lysine-linked maleimidopropionic acid group, resulting in a shorter plasma half-life that more closely reflects natural GHRH pulsatility characteristics. This makes it a valuable investigative tool for studying acute GH release mechanisms and hypothalamic-pituitary axis regulation in controlled laboratory settings.
Biochemical Characteristics
- Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
- Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
- Molecular Weight: 3,367.97 g/mol
- CAS Number: 863288-34-0
Sequence Modifications:
- Position 2: Alanine → D-Alanine (prevents DPP-IV cleavage)
- Position 8: Asparagine → Alanine (prevents asparagine rearrangement)
- Position 15: Glycine → Alanine (enhances stability)
- Position 27: Methionine → Leucine (prevents oxidation)
- C-terminus: Amidated (increases receptor binding affinity in research models)
Primary Receptor Target: Selective agonist of the Growth Hormone Releasing Hormone Receptor (GHRH-R), investigated for its role in stimulating pulsatile growth hormone secretion from anterior pituitary somatotrophs in preclinical models.
Research Applications
CJC-1295 (No DAC) is utilized exclusively within laboratory research workflows to evaluate growth hormone-related signaling processes. Common experimental applications include:
Neuroendocrine Signaling Studies
Investigating GHRH receptor activation, cAMP/PKA pathway signaling, and hypothalamic-pituitary-somatotroph axis dynamics under controlled experimental conditions.
GH Secretagogue Research
Evaluating signaling interactions when combined with ghrelin mimetics including GHRP-6, GHRP-2, Ipamorelin, and Hexarelin to examine GH pulse amplitude dynamics in preclinical models.
Metabolic Research Models
Studying downstream effects on IGF-1 production, lipolytic signaling, nitrogen retention, and lean tissue accretion endpoints in controlled experimental systems.
Age-Related Somatotropic Research
Examining somatopause mechanisms and GH secretion pattern changes in aged animal models under defined laboratory conditions.
Circadian & Sleep Architecture Research
Assessing the relationship between pulsatile GH release patterns and slow-wave sleep architecture in preclinical research paradigms.
Tissue Remodeling & Repair Models
Investigating the role of GH/IGF-1 signaling in wound-healing endpoints, bone density markers, and connective tissue remodeling in controlled laboratory settings.
Pathway & Mechanistic Context
Research documents CJC-1295 (No DAC) involvement in several interconnected signaling networks:
GHRH Receptor Activation
CJC-1295 (No DAC) binds selectively to the GHRH receptor (GHRH-R), a G-protein coupled receptor expressed primarily on anterior pituitary somatotrophs. This binding activates adenylyl cyclase, increasing intracellular cAMP levels and triggering PKA-mediated signaling cascades in experimental models.
Pulsatile GH Release Dynamics
Unlike the DAC-conjugated variant, CJC-1295 (No DAC) produces acute GH pulses with a plasma half-life of approximately 30 minutes in preclinical pharmacokinetic studies. This characteristic preserves physiological pulsatility patterns relevant to receptor sensitivity research and downstream signaling investigations.
IGF-1 Axis Signaling
GH release in experimental models stimulates hepatic production of Insulin-like Growth Factor-1 (IGF-1), which mediates downstream anabolic signaling cascades attributed to the GH axis in preclinical research systems.
Synergistic Receptor Pathway Modeling
When combined with GHRP-class peptides in laboratory settings, CJC-1295 (No DAC) demonstrates amplified GH release through complementary receptor activation — GHRH-R (Gs-coupled, cAMP pathway) and GHS-R1a (Gq-coupled, IP3/DAG pathway) — providing a useful model for studying multi-receptor signaling dynamics.
Somatostatin Pathway Interplay
The peptide's activity in experimental systems is modulated by endogenous somatostatin, which provides negative feedback on GH secretion. Timing of administration relative to natural somatostatin signaling patterns is a relevant variable in experimental protocol design.
Preclinical Research Summary
1. Pituitary Function Studies
In-vitro studies using primary pituitary cell cultures demonstrate dose-dependent GH release endpoints following CJC-1295 (No DAC) exposure, with amplified secretion observed when co-administered with ghrelin analogs under controlled conditions.
2. Metabolic Research Models
Rodent models have evaluated lean body mass markers, adiposity endpoints, and serum IGF-1 levels as experimental readouts following defined administration protocols.
3. Aging & Somatopause Research
Studies in aged animal models examine GH pulse amplitude and frequency dynamics, with corresponding metabolic marker assessments as experimental endpoints.
4. Combination Signaling Studies
Research combining CJC-1295 (No DAC) with Ipamorelin or GHRP-2 documents synergistic amplification of GH release endpoints, providing a framework for studying multi-secretagogue receptor pathway interactions.
5. Pharmacokinetic Characterization
Plasma half-life studies confirm rapid clearance of approximately 30 minutes compared to CJC-1295 with DAC (6–8 days), validating its utility as a research tool for studying acute pulsatile GH secretion dynamics in preclinical models.
Form & Analytical Testing
CJC-1295 (No DAC) is supplied as a sterile lyophilized powder manufactured via solid-phase peptide synthesis (SPPS) using Fmoc chemistry. Each production lot undergoes analytical verification using:
- HPLC — purity profiling and lot consistency
- Mass Spectrometry (MS) — molecular identity confirmation
Purity & Quality
- ≥99% Purity — HPLC Verified
- Independently tested by accredited third-party laboratory
- Certificate of Analysis (CoA) available for every batch
Research Use Only (RUO) Notice
All products are furnished strictly for in-vitro laboratory research use only. "In-vitro" refers to studies conducted outside of a living organism under controlled experimental conditions. These materials are not pharmaceuticals, drugs, or therapeutic agents and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.
